Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555866 · ClinicalTrials.gov registry record · Phase 1
Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT01555866 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 49 participants.
The verdict
NCT01555866, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a 2-part, open-label study, designed to evaluate the effect of renal disease on the pharmacokinetics of BAL4815 (active isavuconazole moiety) relative to the pharmacokinetics in healthy subjects with normal renal function.
Interventions
- DRUG isavuconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555866
The ClinicalTrials.gov registry entry for NCT01555866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which isavuconazole is the first listed.
NCT01555866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555866 about?
NCT01555866 is a clinical study titled "Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.". This is a 2-part, open-label study, designed to evaluate the effect of renal disease on the pharmacokinetics of BAL4815 (active isavuconazole moiety) relative to the pharmacokinetics in healthy subjects with normal renal function.
What is the current status of trial NCT01555866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2012-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01555866?
The interventions under investigation include: isavuconazole (DRUG).
Who is sponsoring clinical trial NCT01555866?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.